Memento MedicaHistory of medicine & the mind
All stories

Drug safety, pregnancy & regulatory judgment · Washington, D.C., 1960–1962

Frances Kelsey and the File That Would Not Close

In 1960, a new FDA reviewer received a drug application expected to pass quickly. Her refusal to treat missing evidence as proof of safety changed American medicine.

6 minute read · 1,231 words · Published October 26, 2026

An anonymous woman reviews blank papers beside tied files in a rain-darkened mid-century office.
AI conceptual illustration of regulatory review in a 1960 federal office. It is not Frances Kelsey, her actual office, or a documented moment.

Content note: Medication injury, pregnancy loss, congenital limb differences, and failures of informed consent; no graphic imagery.

The application arrived with a deadline built into the law. In September 1960, the William S. Merrell Company asked the United States Food and Drug Administration to permit the sale of Kevadon, its brand of thalidomide. If the agency did not object within the review period, the application could take effect.

Frances Oldham Kelsey had joined the FDA only weeks earlier. Thalidomide was already sold in many countries as a sedative, and the company expected an American launch before the winter holiday season. The file on her desk carried the weight of international acceptance, corporate urgency, and a system that asked a small group of medical officers to decide whether the evidence was enough.

Kelsey did not have proof that thalidomide caused severe fetal injury. What she had was an application she considered incomplete, unresolved questions about how the drug moved through the body, and reports of nerve damage after prolonged use. She kept asking for better evidence.

The file would return. So would the company. Each delay looked temporary until reports from Germany and Australia revealed what the missing evidence had concealed.

A new reviewer and an old promise

American drug law in 1960 required a manufacturer to submit evidence of safety before marketing a new drug. It did not yet demand the modern demonstration of effectiveness through adequate, well-controlled studies. Review therefore depended not only on what a company supplied, but on whether an examiner recognized what the submission failed to answer.

Kelsey was not an accidental obstacle. She had trained in pharmacology and medicine and had worked with E. M. K. Geiling on the investigation of Elixir Sulfanilamide, a medicine whose toxic solvent killed more than one hundred people in 1937. That disaster had helped produce the 1938 law under which she now reviewed new drugs. The lesson was institutional as well as scientific: a product could look ordinary, arrive with professional assurances, and still contain a catastrophe.

The FDA’s own history describes medical officers as a small group responsible for evaluating new-drug applications. Kelsey’s assignment was not to prove that Kevadon was dangerous. It was to determine whether the sponsor had shown it to be safe. Those are different burdens, and the space between them became the center of the case.

The application also arrived during a period of rapid pharmaceutical expansion. New antibiotics, tranquilizers, and other medicines had strengthened public confidence in modern drugs. Success created its own pressure: a medicine used abroad could appear to be an advance that American patients were being denied. A reviewer had to separate the social fact of popularity from the scientific fact of adequate testing.

Sources [1] · [2] · [3]

What the application did not settle

Merrell presented thalidomide as an unusually safe sedative. Yet Kelsey found the supporting material inadequate. The company continued to submit information, and she continued to withhold approval. FDA accounts describe ongoing pressure from the firm, but the decisive point was less dramatic than a single confrontation: the evidence did not become reliable merely because the request was repeated.

She questioned the drug’s absorption and distribution. If apparently low toxicity reflected poor absorption in some settings, that reassurance might not hold in every person or physiological state. She was also concerned about use during pregnancy and about a British report associating prolonged thalidomide exposure with peripheral neuritis. None of these observations, alone, established the fetal syndrome that would later become clear. Together, they made certainty about safety impossible.

This distinction matters. Kelsey is sometimes remembered as if she foresaw every injury in advance. The record supports a more useful kind of judgment. She saw that uncertainty had not been resolved and refused to convert an absence of adequate evidence into a clean bill of health.

Sources [1] · [2] · [4]

A deadline that kept restarting

Under the process then in place, the company’s supplemental submissions could restart the review period. The application did not simply reach a final hearing where one side won. It moved through letters, questions, amendments, visits, and another interval in which approval remained pending.

For Merrell, delay meant warehouses, plans, and a market waiting to open. For the reviewer, speed could not repair missing data. Kelsey’s leverage came from the narrow authority to say that the submission was still not enough. She used it repeatedly, while colleagues at the agency supported the request for more information.

The pressure was real, but later hero stories can flatten the institutional setting. Kelsey worked inside an agency, under a statute, with supervisors and other reviewers. Her persistence mattered because the system still left room for scientific doubt to interrupt commercial momentum.

That interruption was mostly administrative work. It meant reading another submission, locating the unanswered question, writing again, and accepting that caution might look like obstruction to people who wanted a final answer. The drama came later. At the time, the protective act was the repeated refusal to close a file whose central uncertainty remained open.

Sources [1] · [2] · [5]

The evidence arrives from elsewhere

By late 1961, physicians in Germany and Australia had connected thalidomide exposure in pregnancy with a striking rise in severe congenital differences, including absent or shortened limbs and injuries affecting other organs. The pattern transformed a question about insufficient testing into an international disaster.

Kevadon had not been approved for commercial sale in the United States. That did not mean no Americans had received it. FDA history records that Merrell distributed more than two million tablets through investigational use, in a regulatory environment that left such distribution loosely controlled. Some women were given the experimental drug without being told that its safety had not been established.

The distinction between a smaller American toll and no American exposure is essential. Kelsey’s review prevented a national market launch. It did not create a perfect barrier, and the later recovery of investigational supplies showed how many routes existed around the formal approval decision.

Sources [1] · [2] · [4] · [6]

A private decision becomes public law

News of the thalidomide disaster changed the political meaning of a drug file. Congress had already been considering Senator Estes Kefauver’s proposals to strengthen pharmaceutical regulation. In October 1962, President John F. Kennedy signed the Kefauver-Harris amendments.

The amendments required manufacturers to establish effectiveness as well as safety before marketing. They expanded oversight of clinical investigations and required fuller reporting to the FDA. The new framework also addressed informed consent, a direct response to a system in which people could receive experimental drugs without understanding that they were research subjects.

Kelsey received the President’s Award for Distinguished Federal Civilian Service in 1962. The medal recognized a refusal, but the lasting change was procedural: more evidence would have to exist before a company could ask the public to bear uncertainty.

Sources [2] · [3] · [6]

What caution can and cannot promise

Drug review always carries two possible errors. An unsafe or ineffective treatment can be allowed onto the market. A useful treatment can be delayed. The Kelsey story does not erase that tension or turn delay itself into virtue.

It demonstrates something narrower. When a sponsor holds the evidence and the public will carry the harm, unresolved questions cannot be treated as empty space. A deadline, foreign approval, professional testimonials, and commercial confidence do not answer a biological question.

The later recognition of thalidomide’s harms can make refusal seem easy in retrospect. It was difficult precisely because the decisive pattern had not yet appeared in the application. Regulatory judgment had to operate before certainty, using standards for evidence rather than knowledge of the ending.

The file on Kelsey’s desk did not contain a picture of the future. It contained gaps. Her achievement was to keep those gaps visible long enough for the world’s evidence to catch up.

Sources [1] · [2] · [3]

More stories from Memento Medica

For more interesting content, follow Memento Medica on YouTube.

Follow Memento Medica

Written and illustrated with AI assistance for Memento Medica. The lead image is a conceptual reconstruction, not a historical photograph or a likeness of Frances Kelsey. Factual claims were checked against the references listed below.

Sources & what we can know

This original narrative distinguishes what Kelsey knew during review from what became clear after international case reports. It does not claim that she predicted the full fetal syndrome, that no Americans received thalidomide, or that one reviewer alone created the 1962 law. Follow Memento Medica for more independently sourced stories from the history of medicine.

  1. FDA: Frances Oldham Kelsey—Medical reviewer famous for averting a public health tragedy

    Official FDA biographical history, read October 26, 2026. Used for Kelsey’s training, assignment, repeated requests for reliable evidence, company pressure, and later FDA service.

  2. FDA: A Brief History of the Center for Drug Evaluation and Research

    Official institutional history, relevant sections read October 26, 2026. Used for the Kevadon application, investigational distribution, 1962 amendments, informed consent, and agency structure.

  3. FDA: Promoting Safe and Effective Drugs for 100 Years

    Official regulatory history, read October 26, 2026. Used for the pre-1962 legal framework and the public impact of Kelsey’s decision.

  4. FDA historical account of Frances Kelsey and thalidomide

    FDA-hosted historical document, relevant extracted text read October 26, 2026. Used for questions about absorption, fetal exposure, and the report of peripheral neuritis.

  5. University of Chicago Medicine: How a physician-scientist saved the U.S. from a birth-defects catastrophe

    Institutional biography, read October 26, 2026. Used for Kelsey’s earlier pharmacology work and professional context; no precise global casualty estimate adopted.

  6. FDA: Protection of Human Subjects; Informed Consent; Proposed Rule

    Official rulemaking history, relevant legislative-history section read October 26, 2026. Used for investigational thalidomide exposure and the 1962 informed-consent provisions.